Technology evaluation: Canvaxin, John Wayne Cancer Institute/CancerVax.
CancerVax and the John Wayne Cancer Institute are co-developing Biotechnology Tumor antigen Canvaxin, a vaccine containing over 20 tumor antigens, for the potential treatment of melanoma and colon cancer. Canvaxin is currently undergoing phase III clinical trials for melanoma and a phase II trial for colon cancer.